Abstract
This article represents the first stage of a research in using a direct oral inhibitor of Xa factor, Rivaroxaban, in patients after cementless hip joint arthroplasty. The purpose of the present research was to study the efficacy and safety of the above drug preparation. The investigation involved 20 patients. The efficacy of this anticoagulant therapy was analysed; its assessment did not reveal either any manifestations of thrombotic complications (thrombosis of deep veins on the lower extremities, pulmonary thromboembolism) or cases of haemorrhagic complications. The safety was assessed by the results of general clinical and biochemical blood tests. This research demonstrated that taking of Rivaroxaban ensured high efficacy of anticoagulant therapy for preventing thromboembolic complications and preserved safety for patients after hip joint arthroplasty.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
